$1,318.00
Datamonitor Healthcare estimates that in 2019, there were approximately 121.1 million seropositive prevalent cases of celiac disease and 48.0 million prevalent cases of biopsy-proven celiac disease worldwide.
This Market Spotlight report covers the Celiac Disease market, comprising key pipeline drugs, clinical trials, upcoming events, probability of success, and a 10-year disease prevalence forecast
Key Takeaways
CONTENTS
5 OVERVIEW
6 KEY TAKEAWAYS
7 DISEASE BACKGROUND
7 Subtypes
9 TREATMENT
10 EPIDEMIOLOGY
12 PIPELINE DRUGS
16 KEY UPCOMING EVENTS
17 PROBABILITY OF SUCCESS
18 CLINICAL TRIAL LANDSCAPE
19 Sponsors by status
20 Sponsors by phase
21 BIBLIOGRAPHY
22 APPENDIX
LIST OF FIGURES
12 Figure 1: Overview of pipeline drugs for celiac disease in the US
12 Figure 2: Pipeline drugs for celiac disease, by company
13 Figure 3: Pipeline drugs for celiac disease, by drug type
13 Figure 4: Pipeline drugs for celiac disease, by classification
16 Figure 5: Key upcoming events in celiac disease
17 Figure 6: Probability of success in the autoimmune/immunology pipeline
18 Figure 7: Clinical trials in celiac disease
18 Figure 8: Top 10 drugs for clinical trials in celiac disease
19 Figure 9: Top 10 companies for clinical trials in celiac disease
19 Figure 10: Trial locations in celiac disease
20 Figure 11: Celiac disease trials status
20 Figure 12: Celiac disease trials sponsors, by phase
LIST OF TABLES
10 Table 1: Prevalent cases of celiac disease, by definition, 2019
11 Table 2: Prevalence of celiac disease, by definition
14 Table 3: Pipeline drugs for celiac disease in the US
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!